Extract
Interferon (IFN)-β has been classified as a drug that is possibly associated with development of pulmonary arterial hypertension (PAH), a devastating disease that can lead to right heart failure and premature death [1].
Abstract
The possible causal relationship between interferon-β exposure and pulmonary arterial hypertension development requires close follow-up of patients on treatment with interferon-β http://bit.ly/2OPGSVP
Footnotes
Conflict of interest: A. Anthi has nothing to disclose.
Conflict of interest: E. Stagaki has nothing to disclose.
Conflict of interest: L. Rallidis has nothing to disclose.
Conflict of interest: D. Konstantonis has nothing to disclose.
Conflict of interest: M-E. Evangelopoulos reports grants and personal fees from Biogen and Novartis, and personal fees from Merck-Serono, outside the submitted work.
Conflict of interest: K. Voumvourakis has nothing to disclose.
Conflict of interest: A. Armaganidis has nothing to disclose.
Conflict of interest: S.E. Orfanos reports grants from GSK and nonfinancial support from Pharmaserve–Lilly outside the submitted work.
- Received December 3, 2019.
- Accepted February 6, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.